New Delhi: After finalising the Daichii Sankyo deal in June Pharma major, Ranbaxy re-constituted its board of directors on Friday.
The current Ranbaxy CEO and MD, Malvinder Singh Mohan, will assume the additional role of an Executive Chairman. Ranbaxy will remain a public listed company and will have five members on the board while Daichii will be represented by four members.
In June the Japanese drugmaker Daichii had picked up 63.9 per cent stake in Ranbaxy for Rs 19,803 crore.
The company has also appointed Ranbaxy Laboratories Chief Operating Officer Atul Sobti as COO in the company's board. Daiichi Sankyo President & Chief Executive Officer, Takashi Shoda, will be the one of the company's new Board of Directors.
The other members in the board are Daiichi Sankyo Senior Executive Officer Tstomu Une, Religare Enterprise Ltd CEO Sunil Godhwani, BOWS Pharmaceuticals AG General Partner Anthony H Wild, Mukand Ltd Co-Chairman and MD Rajesh V Shah, GCA Savvian Group Representative Director Akihiro Watanbe and Advocate Balinder Singh Dhillon.
Singh has also become a member of the senior global management team of Daiichi Sankyo, the company said in a statement.
"Ranbaxy will maintain its status as a publicly listed company and will continue to operate as an independent and autonomous entity," a statement released by the Gurgaon-based pharma company read.
(With inputs from agencies)
Comments
0 comment